 |
 |
Navigant Consulting Estimates the Market for Worldwide Movement Disorders Will Reach $4 Billion by 2009 March 10, 2004 12:30 PM US Eastern Timezone SAN MATEO, Calif.--(BUSINESS WIRE)--March 10, 2004--Study identifies 11 new potential products to enter the market in the next five years With the worldwide prevalence of movement disorders, including Parkinson's disease (PD), Huntington's disease (HD) and amyotrophic lateral sclerosis (ALS), estimated at approximately four million people in 2004 (based on U.S. Census Bureau data and epidemiology studies), Navigant Consulting, Inc.'s (NYSE:NCI) Front Line Strategic Market Reports(TM) analysts have found there is increasing demand for effective therapeutics to delay disease progression and improve the quality of life for patients. In their recently concluded study entitled "Movement Disorders Therapeutics: Physician Perspectives and Competitive Benchmarking Analysis of a High Growth Market," the analysts also determined that there will be sustained revenue expansion in this neurodegenerative disease segment as few current drugs effectively treat the disorders, and several novel products are poised to enter the U.S. market by 2009. "With the increased aging of the population, there is a higher percentage of patients with neurodegenerative movement disorders such as Parkinson's disease," said neurologist Gajanan Nilaver of Portland, Oregon. According to Navigant Consulting's research and analysis, the worldwide movement disorders market will surpass $2 billion by the end of 2004 and increase to $4 billion by the end of 2009, driven by the introduction of 11 new products, expanding patient populations and improved diagnostic tests. Dopamine receptor agonists, the standard treatment for PD, will continue to be the leading class in the movement disorders category, led by top-sellers Mirapex (pramipexole), currently marketed by Pfizer and Boehringer Ingelheim, and Cabaser (cabergoline), also marketed by Pfizer. However, there will be several new PD treatments entering the market, including CEP 1347, Cephalon's mixed-lineage kinase inhibitor, and Aderis Pharmaceuticals' Rotigotine CDS Patch, a transdermal dopamine receptor agonist. More exciting are the new entrants for HD and ALS. LAX 101, following its projected launch in 2008, is expected to be adopted quickly as it will be the first therapeutic specifically indicated for HD. In the ALS segment, IGF-1 and minocycline are expected to be launched in 2007 and 2008, respectively, and are expected to generate significant revenue by 2009. "As more government funding has been allocated to disease causality studies in recent years, researchers are increasing their understanding of the specific mechanisms of movement disorders, such as mitochondrial dysfunction, programmed cell death, and neural damage via environmental toxins. As a result, more effective treatments are emerging, especially for HD and ALS, while emerging PD therapeutics offer improved safety profiles," said Rochelle Ellis, Associate for Front Line Strategic Market Reports, Navigant Consulting. "The physicians we surveyed strongly expressed the need for improved medicines and outlined their criteria for prescribing one product over another. We feel our competitive benchmark analysis will provide timely, in-depth information to help current and emerging drug manufacturers position their products for optimized profitability." Primary information for the study was gathered by conducting a web-based survey of a panel of physician experts from across the country with extensive experience in treating PD, HD and ALS. Supporting information was also collected through discussions with pharmaceutical company representatives and from secondary sources, including news releases, SEC filings, industry web sites and scientific periodicals. For additional details, complimentary PDF sample pages, or to order "Movement Disorders Therapeutics: Physician Perspectives and Competitive Benchmarking Analysis of a High Growth Market," please contact Anil Patel of Navigant Consulting at 650.525.1500 x135. About Navigant Consulting Navigant Consulting, Inc. (NYSE:NCI) is a specialized independent consulting firm providing litigation, financial, restructuring, energy, healthcare and operational consulting services to government agencies, legal counsel and large companies facing the challenges of uncertainty, risk, distress and significant change. The Company focuses on industries undergoing substantial regulatory or structural change and on the issues driving these transformations. "Navigant" is a service mark of Navigant International, Inc. Navigant Consulting, Inc. (NCI) is not affiliated, associated, or in any way connected with Navigant International, Inc. and NCI's use of "Navigant" is made under license from Navigant International, Inc. More information about Navigant Consulting can be found at http://www.navigantconsulting.com Contacts: Navigant Consulting, Inc. Front Line Strategic Market Reports(TM) Division Molly Varnau, 650-525-1500 ext. 102 [log in to unmask] or Corporate Communications Brent Curry, 312-573-5668 [log in to unmask] SOURCE: Business Wire (press release) http://home.businesswire.com/portal/site/google/index.jsp?ndmViewId=news_view&newsId=20040310005123&newsLang=en * * * ---------------------------------------------------------------------- To sign-off Parkinsn send a message to: mailto:[log in to unmask] In the body of the message put: signoff parkinsn